BACKGROUND: There is intense interest in the role of programmed death 1 (PD-1) in causing persistent T-cell dysfunction in HIV infection. However, the impact of HIV infection and antiretroviral treatment (ART) on the expression of PD-1 on T cells is still poorly defined. METHODS: PD-1 was measured longitudinally in a cohort of recently HIV-infected individuals (n = 121) who started ART early (<6 months after infection) vs. later (≥2 years after infection). PD-1 was also measured cross-sectionally in a diverse cohort of chronically HIV-infected adults (n = 206). RESULTS: PD-1 expression levels were high on CD8⁺ T cells during early HIV infection. PD-1 levels increased on both CD4⁺ and CD8⁺ T cells populations in those who delayed therapy (11 and 10%/year, respectively). PD-1 levels declined and were similar in those treated early vs. late after 1 year of ART. In both cohorts, PD-1 expression on CD4⁺ T cells was associated with CD4⁺ T-cell activation (CD38⁺HLA-DR⁺) and inversely with CD4⁺ cell count. In contrast, PD-1 expression on CD8⁺ T cells was most strongly associated with CD8⁺ T-cell activation and with plasma viral load in viremic individuals. CONCLUSION: Across two large cohorts of untreated and treated individuals, we found consistent associations between HIV RNA levels, CD8⁺ T-cell activation and PD-1 expression on CD8⁺ T cells. In contrast, CD4⁺ T-cell counts and CD4⁺ T-cell activation were more consistent correlates of PD-1 expression on CD4⁺ T cells. PD-1 expression appears to be driven by both direct antigen and homeostatic pathways.
BACKGROUND: There is intense interest in the role of programmed death 1 (PD-1) in causing persistent T-cell dysfunction in HIV infection. However, the impact of HIV infection and antiretroviral treatment (ART) on the expression of PD-1 on T cells is still poorly defined. METHODS:PD-1 was measured longitudinally in a cohort of recently HIV-infected individuals (n = 121) who started ART early (<6 months after infection) vs. later (≥2 years after infection). PD-1 was also measured cross-sectionally in a diverse cohort of chronically HIV-infected adults (n = 206). RESULTS:PD-1 expression levels were high on CD8⁺ T cells during early HIV infection. PD-1 levels increased on both CD4⁺ and CD8⁺ T cells populations in those who delayed therapy (11 and 10%/year, respectively). PD-1 levels declined and were similar in those treated early vs. late after 1 year of ART. In both cohorts, PD-1 expression on CD4⁺ T cells was associated with CD4⁺ T-cell activation (CD38⁺HLA-DR⁺) and inversely with CD4⁺ cell count. In contrast, PD-1 expression on CD8⁺ T cells was most strongly associated with CD8⁺ T-cell activation and with plasma viral load in viremic individuals. CONCLUSION: Across two large cohorts of untreated and treated individuals, we found consistent associations between HIV RNA levels, CD8⁺ T-cell activation and PD-1 expression on CD8⁺ T cells. In contrast, CD4⁺ T-cell counts and CD4⁺ T-cell activation were more consistent correlates of PD-1 expression on CD4⁺ T cells. PD-1 expression appears to be driven by both direct antigen and homeostatic pathways.
Authors: L A Napolitano; R M Grant; S G Deeks; D Schmidt; S C De Rosa; L A Herzenberg; B G Herndier; J Andersson; J M McCune Journal: Nat Med Date: 2001-01 Impact factor: 53.440
Authors: Marta Catalfamo; Michele Di Mascio; Zonghui Hu; Sharat Srinivasula; Vishakha Thaker; Joseph Adelsberger; Adam Rupert; Michael Baseler; Yutaka Tagaya; Gregg Roby; Catherine Rehm; Dean Follmann; H Clifford Lane Journal: Proc Natl Acad Sci U S A Date: 2008-12-05 Impact factor: 11.205
Authors: Rebecca K Lodwick; Caroline A Sabin; Kholoud Porter; Bruno Ledergerber; Ard van Sighem; Alessandro Cozzi-Lepri; Pavel Khaykin; Amanda Mocroft; Lisa Jacobson; Stephane De Wit; Niels Obel; Antonella Castagna; Jan-Christian Wasmuth; John Gill; Marina B Klein; Stephen Gange; Melchor Riera; Cristina Mussini; Félix Gutiérrez; Giota Touloumi; Patrizia Carrieri; Jodie L Guest; Norbert H Brockmeyer; Andrew N Phillips Journal: Lancet Date: 2010-07-15 Impact factor: 79.321
Authors: David M Naeger; Jeffrey N Martin; Elizabeth Sinclair; Peter W Hunt; David R Bangsberg; Frederick Hecht; Priscilla Hsue; Joseph M McCune; Steven G Deeks Journal: PLoS One Date: 2010-01-29 Impact factor: 3.240
Authors: Delphine Sauce; Jorge R Almeida; Martin Larsen; Laurine Haro; Brigitte Autran; Gordon J Freeman; Victor Appay Journal: AIDS Date: 2007-10-01 Impact factor: 4.177
Authors: Leslie Cockerham; Rebecca Scherzer; Andrew Zolopa; David Rimland; Cora E Lewis; Peter Bacchetti; Carl Grunfeld; Michael Shlipak; Phyllis C Tien Journal: J Acquir Immune Defic Syndr Date: 2010-01 Impact factor: 3.731
Authors: Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly Journal: Nat Med Date: 2009-06-21 Impact factor: 53.440
Authors: Rachel Lena Rutishauser; Wendy Hartogensis; Christian Deo Deguit; Melissa Krone; Rebecca Hoh; Frederick M Hecht; Christopher D Pilcher; Peter Bacchetti; Steven G Deeks; Peter W Hunt; Joseph M McCune Journal: AIDS Res Hum Retroviruses Date: 2017-04-25 Impact factor: 2.205
Authors: Geetha H Mylvaganam; Lynette S Chea; Gregory K Tharp; Sakeenah Hicks; Vijayakumar Velu; Smita S Iyer; Claire Deleage; Jacob D Estes; Steven E Bosinger; Gordon J Freeman; Rafi Ahmed; Rama R Amara Journal: JCI Insight Date: 2018-09-20
Authors: Ping Chen; Hui Chen; Maha Moussa; Jie Cheng; Tong Li; Jing Qin; Jeffrey D Lifson; Michael C Sneller; Ludmila Krymskaya; Steven Godin; H Clifford Lane; Marta Catalfamo Journal: J Infect Dis Date: 2020-02-03 Impact factor: 5.226